Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation

Journal of International Medical Research

Volumn 38, Issue 5, 2010, Pages 1617-1625

  Zhang, R ^a   Ran, H H ^a   Zhu, H L ^a   Chen, Q ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cardiovascular diseases; Clopidogrel; Coronary stent; Drug interaction; Esomeprazole; Platelet aggregation; Proton pump inhibitors; Thenopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; ESOMEPRAZOLE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY STENT; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 78449268689     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800506     Document Type: Article

References (21)

1. Laine L, Hennekens C: Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34-41.
2. Juurlink DN, Gomes T, Ko DT, et al: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
3. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al: The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010; 26: e54-e57.
4. Kushner FG, Hand M, Smith SC Jr et al: 2009 focused updates: ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
5. Siller-Matula JM, Spiel AO, Lang IM, et al: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-e5.
6. Sibbing D, Morath T, Stegherr J, et al: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
7. Eisenstein EL, Anstrom KJ, Kong DF, et al: Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
8. Dean J, Yujie Z, Yingxin Z, et al: Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. Clin Cardiol 2009; 32: 164-168.
9. Park SJ, Park DW, Kim YH, et al: Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
10. Aronow HD, Steinhubl SR, Brennan DM, et al: Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events during Observation (CREDO) trial. Am Heart J 2009; 157: 369-374.
11. Petersen JL, Barron JJ, Hammill BG, et al: Clopidogrel use and clinical events after drug- eluting stent implantation: findings from the HealthCore Integrated Research Database. Am Heart J 2010; 159: 462-470.
12. Hallas J, Dall M, Andries A, et al: Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726.
13. Delaney JA, Opatrny L, Brophy JM, et al: Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-351.
14. Ray WA, Murray KT, Griffin MR, et al: Outcomes with concurrent use of clopidogrel and proton- pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-345.
15. Rassen JA, Choudhry NK, Avorn J, et al: Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329.
16. Kazui M, Nishiya Y, Ishizuka T, et al: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
17. Hulot JS, Bura A, Villard E, et al: Cytochrome P450 2C19 loss-of-function polymorphism is a majordeterminantofclopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
18. Shuldiner AR, O'Connell JR, Bliden KP, et al: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
19. Mega JL, Close SL, Wiviott SD, et al: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
20. Simon T, Verstuyft C, Mary-Krause M, et al French Registry of Acute ST-Elevation and Non- ST-Elevation Myocardial Infarction (FAST-MI) Investigators: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
21. Gilard M, Arnaud B, Cornily JC, et al: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.